Tirzepatide (sodium salt)
(Synonyms: LY3298176) 目录号 : GC91871Tirzepatide is an agonist of glucagon-like peptide 1 receptor (GLP-1R) and gastric inhibitory polypeptide (GIP) receptor.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Tirzepatide is an agonist of glucagon-like peptide 1 receptor (GLP-1R) and gastric inhibitory polypeptide (GIP) receptor.[1] It induces cAMP production in HEK293 cells expressing human GLP-1R or human GIP receptor (EC50s = 6.54 and 1.01 nM, respectively). Tirzepatide (100 nM) induces receptor internalization in HEK293 cells expressing human GLP-1R or GIP receptor. In vivo, tirzepatide (10 nmol/kg per day) decreases body weight, food intake, plasma levels of leptin, triglycerides, and free fatty acids (FFAs), hepatic levels of triglycerides, and blood glucose levels in a mouse model of high-fat diet-induced obesity.[2] It prevents A. alternata-induced increases in the numbers of eosinophils and lymphocytes in the bronchoalveolar lavage fluid (BALF) from A. alternata-challenged mice when administered at a dose of 50 nmol/kg every three days.[3] Tirzepatide (50 nmol/kg every three days) inhibits bronchoconstriction induced by the muscarinic receptor agonist methacholine (acetyl-β-methylcholine; ) in a mouse model of diabetes-induced asthma. Formulations containing tirzepatide have been used in the treatment of type 2 diabetes mellitus.
References:
[1].Willard, F.S., Douros, J.D., Gabe, M.B.N., et al.Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonistJCI Insight5(17)e140532(2020).
[2].Samms, R.J., Christe, M.E., Collins, K.A.L., et al.GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese miceJ. Clin. Invest.131(12)e146353(2021).
[3].Toki, S., Zhang, J., Printz, R.L., et al.Dual GIPR and GLP-1R agonist tirzepatide inhibits aeroallergen-induced allergic airway inflammation in mouse model of obese asthmaClin. Exp. Allergy53(2)216-221(2023).
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2077 mL | 1.0387 mL | 2.0775 mL |
| 5 mM | 0.0415 mL | 0.2077 mL | 0.4155 mL |
| 10 mM | 0.0208 mL | 0.1039 mL | 0.2077 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。